Sphero therapeutics

Author: nbgh

August undefined, 2024

WebMar 31, 2024 · Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections. WebAbout Us Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for ...

Spero Therapeutics to Present Data at the 33rd European …

WebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today … WebCAMBRIDGE, Mass., March 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on … film humoris indonesia

Spero Therapeutics Announces Inducement Grants Under

WebProducts Sphero 1.0 and 2.0. The original Sphero was initially prototyped by its inventors, Ian Bernstein and Adam Wilson, with a 3D-printed shell and electronics taken from a smartphone. It was then demonstrated at CES in … WebNews Spero Therapeutics Inc. Significant News Only No significant news for SPRO in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.65 Market Cap $79.38 … WebOct 3, 2024 · Founded in 2013, Spero Therapeutics is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company focuses on treatments with a novel therapeutic approach... group records access

Spero Therapeutics Announces $40 Million Equity Investment ... - Pfizer

Spero Therapeutics - Overview, News & Competitors ZoomInfo.com

WebSpero Therapeutics Reschedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call to March 30, 2024 CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high … WebAug 8, 2024 · Entrepreneur, CEO, Board Member, Author, Physician CEO of Spero Therapeutics, a public, clinical stage company developing a … filmhund hollyWebspero therapeutics, inc. STOCK OPTION AGREEMENT—INCORPORATED TERMS AND CONDITIONS AGREEMENT made as of the date of grant set forth in the Stock Option Grant Notice by and between Spero Therapeutics, Inc. (the “Company”), a Delaware corporation, and the individual whose name appears on the Stock Option Grant Notice (the “Participant”). group records

"WebSpero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial " - Sphero therapeutics

Sphero therapeutics

Spero Therapeutics - Overview, News & Competitors ZoomInfo.com

WebApr 13, 2024 · Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving … WebSep 22, 2024 · Spero Therapeutics, Inc. September 22, 2024, 2:00 AM · 8 min read The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian...

Did you know?

WebSpero Therapeutics Biotechnology Research Cambridge, MA 12,402 followers Multi-Asset, clinical-stage biotech company focused on multidrug-resistant bacterial infections and … WebIf you have a question, comment, concern, or need assistance with your Sphero robot or littleBits kit, please fill out the form below, and a Sphero Customer Advocate will get in …

WebApr 10, 2024 · Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. WebAnalyst Price Forecast Suggests 314.10% Upside. As of April 6, 2024, the average one-year price target for Spero Therapeutics is $6.46. The forecasts range from a low of $5.05 to a high of $8.40 ...

WebMar 30, 2024 · Spero Therapeutics, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $47.44 million for the quarter ended December 2024, surpassing the Zacks... WebApr 13, 2024 · Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

WebMar 30, 2024 · Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel...

WebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical … group recovery aftercare community enterpriseWebApr 10, 2024 · Based on Spero Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $51.28 million and a net profit … group records in excelWebApr 10, 2024 · Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial... group records in access queryWebApr 12, 2024 · A high-level overview of Spero Therapeutics, Inc. (SPRO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment … group records in powerappsWebAnalyst Price Forecast Suggests 314.10% Upside. As of April 6, 2024, the average one-year price target for Spero Therapeutics is $6.46. The forecasts range from a low of $5.05 to a high of $8.40 ... group recruiting airsoftWebView the latest Spero Therapeutics Inc. (SPRO) stock price, news, historical charts, analyst ratings and financial information from WSJ. SPRO Spero Therapeutics Inc. Stock Price & … film hunters s.r.oWeb1 day ago · Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments ... group recovery together